Analysis of cystic fibrosis patient survival confirms STAT3 as a CF modifying gene with changing impact over time.
Inga DunscheEllen L RaddatzHaide IsmerSilke HedtfeldSteffi TammSaskia MoserJulia KontsendornBurkhard TümmlerSabina JanciauskieneAnna-Maria DittrichFrauke StankePublished in: Human molecular genetics (2022)
Our results in different birth cohorts identified a time-dependent impact of STAT3 genotype on CF patients' survival and found that improved symptomatic treatment of later-born CF patients obviates STAT3's modifying influence. Consistent with our previous results, STAT3-specific inhibition resulted in increased CFTR expression in the epithelial cell line 16HBE14o-. Thus, care should be taken when CF modifying genes are studied in cross-sectional cohorts as the impact of modifying genes might not be invariant in the light of changing therapeutic regimens.
Keyphrases
- cystic fibrosis
- end stage renal disease
- pseudomonas aeruginosa
- cell proliferation
- ejection fraction
- newly diagnosed
- chronic kidney disease
- cross sectional
- genome wide
- healthcare
- peritoneal dialysis
- prognostic factors
- palliative care
- quality improvement
- chronic obstructive pulmonary disease
- free survival
- pain management
- air pollution